Albert Tanlim, MD
Addiction Medicine · Watseka, ILNPI 1659342665
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 306 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations.
Across 306 payments — averaging $15.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$987
- Novo Nordisk$946
- AstraZeneca$563
- Boehringer Ingelheim$450
- Lilly USA, LLC$426
- Exact Sciences$216
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,56599%
- Education$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 77 | $987 |
| Novo Nordisk | 68 | $946 |
| AstraZeneca | 28 | $563 |
| Boehringer Ingelheim | 30 | $450 |
| Lilly USA, LLC | 26 | $426 |
| Exact Sciences | 12 | $216 |
| AbbVie(2 entities) | 12 | $203 |
| Amgen | 10 | $158 |
| Merck | 10 | $135 |
| Biohaven Pharmaceuticals, Inc. | 5 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $83 |
| Dexcom, Inc. | 4 | $65 |
| Pfizer | 3 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Novartis | 2 | $28 |
| Dynavax Technologies Corporation | 2 | $21 |
| Mylan Specialty L.p. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$4,609 in reported general payments places this provider in the 85th percentile of 47 addiction medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 99 | $82,191 |
| EliquisApixaban | 85 | $72,898 |
| OzempicSemaglutide | 63 | $71,346 |
| RybelsusSemaglutide | 30 | $64,344 |
| MounjaroTirzepatide | 44 | $49,351 |
| JanuviaSitagliptin Phosphate | 39 | $44,930 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $34,209 |
| FarxigaDapagliflozin Propanediol | 40 | $28,084 |
| XareltoRivaroxaban | 27 | $22,642 |
| TrulicityDulaglutide | 27 | $22,429 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $20,651 |
| TradjentaLinagliptin | 29 | $15,480 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,868 |
| MyrbetriqMirabegron | 16 | $12,805 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $10,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $946 | $135,69093 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $450 | $103,926139 claims |
| PfizerEliquis | $43 | $72,89885 claims |
| Lilly USA, LLCMounjaro, Trulicity | $426 | $71,78071 claims |
| MerckJanuvia, Dulera | $135 | $49,82253 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $563 | $44,35375 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $987 | $41,14759 claims |
| Sanofi-aventis U.S. LLCLantus | $43 | $3,81126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 47 addiction medicine providers in Illinois.
Other addiction medicine in Watseka
- Roueen RafeyanChicago$2.4M
- Abhinav SinglaJoliet$115K
- Leonard SpishakoffRomeoville$11K
- Phillip HeldingHinsdale$8K
- Adeyemi FatokiOttawa$8K
- Michael BlainEldorado$6K
- Francesco TaniChicago$4K
- Neha DattaOrland Park$4K
- Paul BonucciPrinceton$3K
- Risha FennellNormal$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.